Research Efforts Seeking to Raise the Bar in Low-Risk MDS

Rami Komrokji, MD, discusses the evolution of lower-risk MDS treatments that reflect novel classification systems and trials exploring novel therapies.

Amer Zeidan, MBBS, discusses evolutions in the myelodysplastic syndrome treatment paradigm and ongoing research seeking to improve treatment efficacy.

Amer Zeidan, MBBS, discusses completed and ongoing research evaluating immunotherapy and other novel agents in patients with myelodysplastic syndromes.

Rami Komrokji, MD, discusses several trials that supported the FDA approval of luspatercept for the treatment of patients with MDS with anemia.

The MAXILUS study will evaluate the maximum approved dose of luspatercept in lower-risk myelodysplastic syndrome.

Dr Shallis discusses the ELEMENT-MDS trial in MDS and the potential of intervening with luspatercept before patients become RBC transfusion dependent.

The phase 3 ELEMENT-MDS trial aims to expand access to luspatercept for anemia in non-transfusion dependent lower-risk MDS.

Guillermo Garcia-Manero, MD, discusses the investigation of luspatercept dose levels in patients with low-risk myelodysplastic syndrome who require red blood cell transfusions.

Rory Shallis, MD, discusses the utility of luspatercept in the context of the phase 3 ELEMENT-MDS trial for patients with myelodysplastic syndrome.